Cargando…

Pleuroparenchymal fibroelastosis in patients affected by systemic sclerosis: What should the rheumatologist do?

Pleuroparenchymal fibroelastosis (PPFE) is a rare new interstitial lung disease (ILD) characterized by the fibrotic thickening of the visceral pleura and subadjacent parenchymal areas of the upper lobes This study reveals that patients with ILD-SSc associated with chest HRCT evidence of PPFE require...

Descripción completa

Detalles Bibliográficos
Autores principales: Bargagli, Elena, Mazzei, Maria Antonietta, Orlandi, Martina, Gentili, Francesco, Bellisai, Francesca, Frediani, Bruno, Bergantini, Laura, Carobene, Loredana, Randone, Silvia Bellando, Guiducci, Serena, Cameli, Paolo, Bruni, Cosimo, Cerinic, Marco Matucci
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6617070/
https://www.ncbi.nlm.nih.gov/pubmed/31261523
http://dx.doi.org/10.1097/MD.0000000000016086
_version_ 1783433606843072512
author Bargagli, Elena
Mazzei, Maria Antonietta
Orlandi, Martina
Gentili, Francesco
Bellisai, Francesca
Frediani, Bruno
Bergantini, Laura
Carobene, Loredana
Randone, Silvia Bellando
Guiducci, Serena
Cameli, Paolo
Bruni, Cosimo
Cerinic, Marco Matucci
author_facet Bargagli, Elena
Mazzei, Maria Antonietta
Orlandi, Martina
Gentili, Francesco
Bellisai, Francesca
Frediani, Bruno
Bergantini, Laura
Carobene, Loredana
Randone, Silvia Bellando
Guiducci, Serena
Cameli, Paolo
Bruni, Cosimo
Cerinic, Marco Matucci
author_sort Bargagli, Elena
collection PubMed
description Pleuroparenchymal fibroelastosis (PPFE) is a rare new interstitial lung disease (ILD) characterized by the fibrotic thickening of the visceral pleura and subadjacent parenchymal areas of the upper lobes This study reveals that patients with ILD-SSc associated with chest HRCT evidence of PPFE require close and recurrent follow-up with periodic evaluation of lung function parameters, DLCO and chest HRCT. Rheumatologists should be aware of this new radiological finding which is accompanied by a negative prognosis, especially when associated with a progressive course. Patients with this radiological pattern need to be monitored with particular attention.
format Online
Article
Text
id pubmed-6617070
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-66170702019-07-22 Pleuroparenchymal fibroelastosis in patients affected by systemic sclerosis: What should the rheumatologist do? Bargagli, Elena Mazzei, Maria Antonietta Orlandi, Martina Gentili, Francesco Bellisai, Francesca Frediani, Bruno Bergantini, Laura Carobene, Loredana Randone, Silvia Bellando Guiducci, Serena Cameli, Paolo Bruni, Cosimo Cerinic, Marco Matucci Medicine (Baltimore) Research Article Pleuroparenchymal fibroelastosis (PPFE) is a rare new interstitial lung disease (ILD) characterized by the fibrotic thickening of the visceral pleura and subadjacent parenchymal areas of the upper lobes This study reveals that patients with ILD-SSc associated with chest HRCT evidence of PPFE require close and recurrent follow-up with periodic evaluation of lung function parameters, DLCO and chest HRCT. Rheumatologists should be aware of this new radiological finding which is accompanied by a negative prognosis, especially when associated with a progressive course. Patients with this radiological pattern need to be monitored with particular attention. Wolters Kluwer Health 2019-06-28 /pmc/articles/PMC6617070/ /pubmed/31261523 http://dx.doi.org/10.1097/MD.0000000000016086 Text en Copyright © 2019 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nc/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc/4.0
spellingShingle Research Article
Bargagli, Elena
Mazzei, Maria Antonietta
Orlandi, Martina
Gentili, Francesco
Bellisai, Francesca
Frediani, Bruno
Bergantini, Laura
Carobene, Loredana
Randone, Silvia Bellando
Guiducci, Serena
Cameli, Paolo
Bruni, Cosimo
Cerinic, Marco Matucci
Pleuroparenchymal fibroelastosis in patients affected by systemic sclerosis: What should the rheumatologist do?
title Pleuroparenchymal fibroelastosis in patients affected by systemic sclerosis: What should the rheumatologist do?
title_full Pleuroparenchymal fibroelastosis in patients affected by systemic sclerosis: What should the rheumatologist do?
title_fullStr Pleuroparenchymal fibroelastosis in patients affected by systemic sclerosis: What should the rheumatologist do?
title_full_unstemmed Pleuroparenchymal fibroelastosis in patients affected by systemic sclerosis: What should the rheumatologist do?
title_short Pleuroparenchymal fibroelastosis in patients affected by systemic sclerosis: What should the rheumatologist do?
title_sort pleuroparenchymal fibroelastosis in patients affected by systemic sclerosis: what should the rheumatologist do?
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6617070/
https://www.ncbi.nlm.nih.gov/pubmed/31261523
http://dx.doi.org/10.1097/MD.0000000000016086
work_keys_str_mv AT bargaglielena pleuroparenchymalfibroelastosisinpatientsaffectedbysystemicsclerosiswhatshouldtherheumatologistdo
AT mazzeimariaantonietta pleuroparenchymalfibroelastosisinpatientsaffectedbysystemicsclerosiswhatshouldtherheumatologistdo
AT orlandimartina pleuroparenchymalfibroelastosisinpatientsaffectedbysystemicsclerosiswhatshouldtherheumatologistdo
AT gentilifrancesco pleuroparenchymalfibroelastosisinpatientsaffectedbysystemicsclerosiswhatshouldtherheumatologistdo
AT bellisaifrancesca pleuroparenchymalfibroelastosisinpatientsaffectedbysystemicsclerosiswhatshouldtherheumatologistdo
AT fredianibruno pleuroparenchymalfibroelastosisinpatientsaffectedbysystemicsclerosiswhatshouldtherheumatologistdo
AT bergantinilaura pleuroparenchymalfibroelastosisinpatientsaffectedbysystemicsclerosiswhatshouldtherheumatologistdo
AT carobeneloredana pleuroparenchymalfibroelastosisinpatientsaffectedbysystemicsclerosiswhatshouldtherheumatologistdo
AT randonesilviabellando pleuroparenchymalfibroelastosisinpatientsaffectedbysystemicsclerosiswhatshouldtherheumatologistdo
AT guiducciserena pleuroparenchymalfibroelastosisinpatientsaffectedbysystemicsclerosiswhatshouldtherheumatologistdo
AT camelipaolo pleuroparenchymalfibroelastosisinpatientsaffectedbysystemicsclerosiswhatshouldtherheumatologistdo
AT brunicosimo pleuroparenchymalfibroelastosisinpatientsaffectedbysystemicsclerosiswhatshouldtherheumatologistdo
AT cerinicmarcomatucci pleuroparenchymalfibroelastosisinpatientsaffectedbysystemicsclerosiswhatshouldtherheumatologistdo